{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"description":"The number of patients experiencing a grade 3 or greater adverse event will be reported. The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. Additionally, the relationship of the adverse event(s) to the study treatment will be taken into consideration.","groups":[{"description":"INDUCTION (COURSES 1-4): Patients receive ixazomib citrate PO on days 1, 8, and 15, pomalidomide PO on days 1-21, and dexamethasone PO on days 1, 8, 15, and 22. Treatment repeats every 28 days (courses 1-3) and 56 days (course 4) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> TRANSPLANTATION (COURSE 5): Between 2-4 weeks following Induction, patients undergo ASCT.\n\n\\>\n\n\\> CONSOLIDATION (COURSES 6-9): Beginning 60-120 days following ASCT, patients receive ixazomib citrate, pomalidomide, and dexamethasone as in Induction. Treatment repeats every 28 days (courses 6-8) and 56 days (course 9) for up to 4 courses in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> MAINTENANCE (COURSES 10+): Beginning 0-4 weeks following Consolidation, patients receive ixazomib citrate as in Induction. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\n\\>\n\n\\> Autologous Hematopoietic Stem Cell Transplantation: Undergo ASCT\n\n\\>\n\n\\> Dexamethasone: Given PO\n\n\\>\n\n\\> Ixazomib Citrate: Given PO\n\n\\>\n\n\\> Laboratory Biomarker Analysis: Correlative studies\n\n\\>\n\n\\> Pomalidomide: Given PO","id":"OG000","title":"Treatment (Ixazomib, Pomalidomide, Dexamethasone, ASCT)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"36 months","title":"Number of Patients Experiencing Adverse Events Graded According to the Medical Dictionary for Regulatory Activities (MedDRA) Version (v) 12.1","type":"SECONDARY","unitOfMeasure":"Participants"}